145 related articles for article (PubMed ID: 26517807)
1. Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutation.
Dargaud Y; Jourdy Y; Le Quellec S; Hemker CH; Lindhout T; Castoldi E; Negrier C
Br J Haematol; 2016 Sep; 174(6):993-6. PubMed ID: 26517807
[No Abstract] [Full Text] [Related]
2. Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation.
Dargaud Y; Scoazec JY; Wielders SJ; Trzeciak C; Hackeng TM; Négrier C; Hemker HC; Lindhout T; Castoldi E
Blood; 2015 Feb; 125(9):1497-501. PubMed ID: 25564403
[TBL] [Abstract][Full Text] [Related]
3. [Bleeding time and hemostatic agents].
Roskam J
Rev Med Liege; 1973 Aug; 28(16):565-8. PubMed ID: 4755005
[No Abstract] [Full Text] [Related]
4. Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
Hatsuoka M; Seiki M; Sasaki K; Kashii A
Thromb Res; 1986 May; 42(3):407-12. PubMed ID: 3520941
[No Abstract] [Full Text] [Related]
5. The future of hemostasis management.
Lillicrap D
Pediatr Blood Cancer; 2013; 60 Suppl 1():S44-7. PubMed ID: 23109347
[TBL] [Abstract][Full Text] [Related]
6. Management of the dental patient on anticoagulant medication.
Rada RE
Dent Today; 2006 Aug; 25(8):58-63. PubMed ID: 16925162
[No Abstract] [Full Text] [Related]
7. Supplementation of fibrinogen in acquired bleeding disorders: experience, evidence, guidelines, and licences.
Ranucci M; Solomon C
Br J Anaesth; 2012 Aug; 109(2):135-7. PubMed ID: 22782975
[No Abstract] [Full Text] [Related]
8. Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate.
Schöchl H; Forster L; Woidke R; Solomon C; Voelckel W
Anaesthesia; 2010 Feb; 65(2):199-203. PubMed ID: 19995349
[TBL] [Abstract][Full Text] [Related]
9. New data on FII, FV, FIX and thrombomodulin defects: blood keeps clotting in normal and in peculiar ways.
Girolami A; Ferrari S; Girolami B; Randi ML
Hematology; 2019 Dec; 24(1):232-237. PubMed ID: 31793409
[No Abstract] [Full Text] [Related]
10. Recombinant factor VIIa in the treatment of bleeding.
Midathada MV; Mehta P; Waner M; Fink LM
Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
[TBL] [Abstract][Full Text] [Related]
11. [Use of hemostatic preparations in obstetrical hemorrhages].
Pavlovskiĭ DP; Mikaĭlenko ET
Pediatr Akus Ginekol; 1976; (1):33-7. PubMed ID: 787905
[No Abstract] [Full Text] [Related]
12. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
13. [Injectable hemostatic sponges XStat™: revolution or gadget?].
Hoffmann C; Falzone E; Martinez T; Boutonnet M; Peigne V; Lenoir B
Ann Fr Anesth Reanim; 2014 Nov; 33(11):605-6. PubMed ID: 25450736
[No Abstract] [Full Text] [Related]
14. Laboratory Assessment of Hemostatic and Anticoagulant Therapy.
Adcock DM; Gosselin RC
Semin Thromb Hemost; 2017 Apr; 43(3):242-244. PubMed ID: 28346961
[No Abstract] [Full Text] [Related]
15. [Fibrinogen--critical factor in massive bleeding. A retrospective study of management in trauma].
Erlandsson E; Winstedt D; Tornqvist F; Frigyesi A; Schött U
Lakartidningen; 2011 Nov 2-8; 108(44):2219-23. PubMed ID: 22165181
[No Abstract] [Full Text] [Related]
16. [Diagnostic and therapeutic measures in congenital blood coagulation disorders].
Eggert JH
Dtsch Zahnarztl Z; 1982 Nov; 37(11):877-84. PubMed ID: 6816566
[No Abstract] [Full Text] [Related]
17. Emerging treatment strategies for trauma-induced coagulopathy.
Sorensen B; Fries D
Br J Surg; 2012 Jan; 99 Suppl 1():40-50. PubMed ID: 22441854
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic drugs.
Mannucci PM
N Engl J Med; 1998 Jul; 339(4):245-53. PubMed ID: 9673304
[No Abstract] [Full Text] [Related]
19. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond.
Franchini M; Crestani S; Frattini F; Sissa C; Bonfanti C
Semin Thromb Hemost; 2015 Apr; 41(3):342-7. PubMed ID: 24937097
[TBL] [Abstract][Full Text] [Related]
20. Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?
Jourdy Y; Enjolras N; Le Quellec S; Bordet JC; Négrier C; Vinciguerra C; Dargaud Y
PLoS One; 2017; 12(11):e0188213. PubMed ID: 29145514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
